{"id":24906,"date":"2026-03-22T13:53:12","date_gmt":"2026-03-22T08:23:12","guid":{"rendered":"http:\/\/www.sachdevajk.in\/?p=24906"},"modified":"2026-03-22T13:53:12","modified_gmt":"2026-03-22T08:23:12","slug":"relationship-between-nifty-50-and-mankind-pharma","status":"publish","type":"post","link":"http:\/\/www.sachdevajk.in\/?p=24906","title":{"rendered":"Relationship between Nifty 50 and Mankind Pharma"},"content":{"rendered":"

Title: Relationship between Nifty 50 and Mankind Pharma<\/b><\/p>\n

Author: Manish Kharose

<\/b><\/p>\n

1.Introduction: <\/b><\/p>\n

Mankind Pharma is a leading Indian pharmaceutical company founded in 1991 and based in New Delhi, India. The company is involved in the manufacture and marketing of a wide range of medicine and health care products. The company is committed to providing health care solutions that are accessible and affordable. The company has gained popularity for its well-known products, including Manforce, Prega News, and Gas-O-Fast. Mankind Pharma is a top pharma company in India.<\/p>\n

\u00a0<\/p>\n

2. Objective:<\/b>
To calculate Beta and observe its significance<\/p>\n

\u00a0<\/p>\n

3. Literature Review:<\/b><\/p>\n

The literature on the Nifty 50 and Mankind Pharma has emphasized the significance of the companies in the Indian market, specifically in the context of the financial and pharmaceutical industries. The literature on the Nifty 50 has suggested that the companies included in the top 50 on the National Stock Exchange provide diversified investment opportunities, ensuring strong long-term returns despite the short-term market volatility based on economic conditions, valuation ratios, and global events, and the strategies that help to mitigate the risks, such as systematic investment plans. The literature on the pharmaceutical sector has suggested that the sector has been relatively stable and has provided strong growth potential based on innovation, regulation, and the growing demand for generic drugs in the global market, and the positive impacts of technological and corporate governance advancements. In the context of the literature, Mankind Pharma has emerged as a strong player in the Indian market, specifically in terms of the diversified portfolio in the context of cardiovascular, anti-infective, gastrointestinal, and other segments, along with a strong presence in the context of consumer health products. The literature has emphasized the competitive advantage of Mankind Pharma, specifically in terms of the pricing strategy, extensive distribution network.<\/p>\n

4. Data Collection:<\/b>
Data for Nifty 50 And Mankind Pharma was downloaded from NSE India\u2019s website for the period of 1\/1\/2025 to 31\/12\/2025. The Data was manipulated to get Friday closing prices of Nifty 50 and Mankind Pharma. Weekly returns were calculated. Weekly returns of Nifty 50 are named as X and weekly returns of Spencer\u2019s Retail Limited were named as Y. Y was regressed on X.<\/p>\n

\u00a0<\/p>\n

5.Data Analysis:<\/b><\/p>\n

The following data was derived for the taken time period:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>Y=\u22120.75+1.16X<\/p>\n

N (Observations) = 48<\/p>\n

R Square (R\u00b2) = 0.29<\/p>\n

F (F-statistic) = 19.17<\/p>\n

P-value (for X) = 0.00<\/p>\n

t Stat (for X) = 4.38<\/p>\n

B (Coefficient of X) = 1.16<\/p>\n

\u00a0<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

SUMMARY OUTPUT<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Regression Statistics<\/span><\/i><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Multiple R<\/span><\/p>\n<\/td>\n

\n

0.54<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

R Square<\/span><\/p>\n<\/td>\n

\n

0.29<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Adjusted R Square<\/span><\/p>\n<\/td>\n

\n

0.28<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Standard Error<\/span><\/p>\n<\/td>\n

\n

3.18<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Observations<\/span><\/p>\n<\/td>\n

\n

48.00<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

ANOVA<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\u00a0<\/span><\/i><\/p>\n<\/td>\n

\n

df<\/span><\/i><\/p>\n<\/td>\n

\n

SS<\/span><\/i><\/p>\n<\/td>\n

\n

MS<\/span><\/i><\/p>\n<\/td>\n

\n

F<\/span><\/i><\/p>\n<\/td>\n

\n

Significance F<\/span><\/i><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Regression<\/span><\/p>\n<\/td>\n

\n

1.00<\/span><\/p>\n<\/td>\n

\n

193.36<\/span><\/p>\n<\/td>\n

\n

193.36<\/span><\/p>\n<\/td>\n

\n

19.17<\/span><\/p>\n<\/td>\n

\n

0.00<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Residual<\/span><\/p>\n<\/td>\n

\n

46.00<\/span><\/p>\n<\/td>\n

\n

464.06<\/span><\/p>\n<\/td>\n

\n

10.09<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

Total<\/span><\/p>\n<\/td>\n

\n

47.00<\/span><\/p>\n<\/td>\n

\n

657.42<\/span><\/p>\n<\/td>\n

\n

\u00a0<\/span><\/p>\n<\/td>\n

\n

\u00a0<\/span><\/p>\n<\/td>\n

\n

\u00a0<\/span><\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\u00a0<\/span><\/i><\/p>\n<\/td>\n

\n

Coefficients<\/span><\/i><\/p>\n<\/td>\n

\n

Standard Error<\/span><\/i><\/p>\n<\/td>\n

\n

t Stat<\/span><\/i><\/p>\n<\/td>\n

\n

P-value<\/span><\/i><\/p>\n<\/td>\n

\n

Lower 95%<\/span><\/i><\/p>\n<\/td>\n

\n

Upper 95%<\/span><\/i><\/p>\n<\/td>\n

\n

Lower 95.0%<\/span><\/i><\/p>\n<\/td>\n

\n

Upper 95.0%<\/span><\/i><\/p>\n<\/td>\n<\/tr>\n

\n

Intercept<\/span><\/p>\n<\/td>\n

\n

-0.75<\/span><\/p>\n<\/td>\n

\n

0.46<\/span><\/p>\n<\/td>\n

\n

-1.63<\/span><\/p>\n<\/td>\n

\n

0.11<\/span><\/p>\n<\/td>\n

\n

-1.68<\/span><\/p>\n<\/td>\n

\n

0.17<\/span><\/p>\n<\/td>\n

\n

-1.68<\/span><\/p>\n<\/td>\n

\n

0.17<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

X<\/span><\/p>\n<\/td>\n

\n

1.16<\/span><\/p>\n<\/td>\n

\n

0.27<\/span><\/p>\n<\/td>\n

\n

4.38<\/span><\/p>\n<\/td>\n

\n

0.00<\/span><\/p>\n<\/td>\n

\n

0.63<\/span><\/p>\n<\/td>\n

\n

1.70<\/span><\/p>\n<\/td>\n

\n

0.63<\/span><\/p>\n<\/td>\n

\n

1.70<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

6.Conclusion:<\/b><\/p>\n

Hence beta is <\/b>1.16 invest in this company for short period.<\/p>\n

7.Referrence:<\/b><\/p>\n

\u00a0<\/span>William F. Sharpe (1964). Capital Asset Prices: A Theory of Market Equilibrium under Conditions of Risk<\/i>. The Journal of Finance, 19(3), 425\u2013442. <\/b><\/p>\n

\u00a0<\/span>Jack L. Treynor (1961). Market Value, Time, and Risk<\/i>. Unpublished manuscript.<\/b><\/p>\n

\u00a0<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"

Title: Relationship between Nifty 50 and Mankind Pharma Author: Manish Kharose 1.Introduction: Mankind Pharma is a leading Indian pharmaceutical company founded in 1991 and based in New Delhi, India. The company is involved in the manufacture and marketing of a wide range of medicine and health care products. The company is committed to providing health… Continue reading Relationship between Nifty 50 and Mankind Pharma<\/span><\/a><\/p>\n","protected":false},"author":140146,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-24906","post","type-post","status-publish","format-standard","hentry","category-uncategorized","entry"],"_links":{"self":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/24906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/users\/140146"}],"replies":[{"embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24906"}],"version-history":[{"count":1,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/24906\/revisions"}],"predecessor-version":[{"id":24907,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=\/wp\/v2\/posts\/24906\/revisions\/24907"}],"wp:attachment":[{"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24906"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.sachdevajk.in\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}